• Purified human CD8 T-cells

    Erin Zwack/Brodsky Lab & Penn Vet Imaging Core - Murine macrophages infected with Yersinia pseudo tuberculosis. Blue indicates the cell, red is a mitochondrial stain, green is a stain for Yersinia secreted effector proteins.

  • 3D image of the inflamed meningeal membrane of a CX3CR1-GFP reporter mouse

    Claudio Giraudo - Polarization of lytic granules to the immunological synapse during the cytolytic process of human CD8 lymphocytes against cancer cells.

  • Time series of cells expressing GFP-tagged ebola viral protein VP40

    Gretchen Harms, Hunter lab - Stylized images of CD8+ T cells looking at differential localization of the transcription factor T-bet in mouse cells after infection with the parasite Toxoplasma gondii, using the Amnis ImageStream. In the cell in the first and third box, T-bet (red) does not co-localize with DAPI (blue), indicating that it is cytoplas

IFI Members in the News

Cancer Checkpoint Drug Target Governs Metabolic Changes in Exhausted T Cells

August 2, 2016

Reprogramming of the molecular pathways underlying normal metabolism is essential for T cell infection-fighting function and for the immune system to form a “memory” of the microbes it has already encountered. But exactly how metabolism in exhausted T cells is maintained in chronic infections and cancer is a missing element in this line of research. Now, a new study suggests that tweaking metabolic steps in combination with checkpoint blockade drugs may improve some cancer therapies, according to new research from the Perelman School of Medicine at the University of Pennsylvania. The team led by senior author E. John Wherry, PhD, director of the Institute for Immunology, a professor of Microbiology, and co-director of the Parker Institute for Cancer Immunotherapy at Penn.published their findings this week in Immunity.

Read more


Setting the Body's Serial Killers' Loose on Cancer

August 2, 2016

A front-page New York Times article details progress in the field of personalized cellular therapies, including at Penn’s Abramson Cancer Center. The story features Penn Pathology and Laboratory Medicine faculty members Carl June, MD, and Bruce Levine, PhD, and three Abramson Cancer Center patients who participated in clinical trials for the Penn-developed CAR T cell therapy for leukemia. Upon learning his body had been cleared of cancer, “it was like this weight that had been sitting there was gone,” said Doug Olson, who was among the first three patients to receive the therapy and remains cancer-free six years later.

Read more


Philadelphia Researchers are Leaders in Major Effort to Cure HIV

July 14, 2016

The National Institutes of Health named six large scientific teams, including one co-led by the Perelman School of Medicine at the University of Pennsylvania, to advance the global efforts to develop a cure for HIV. James Riley, PhD, an associate professor of Microbiology, will serve as the principal investigator for the $23 million grant.

Read more


A Young Doctor Fights to Cure his Own Rare, Deadly Disease

July 13, 2016

David Fajgenbaum, MD, a research assistant professor in the division of Translational Medicine and Human Genetics, is profiled in a Science magazine article. Fajgenbaum is a Castleman’s disease researcher who was also diagnosed with the rare disease five years ago.

Read more


22 Ways Drinking Soda Will Shorten Your Life

July 11, 2016

The Epoch Times quoted Nehal N. Mehta, MD, MSCE, FACP, FACC, an adjunct assistant professor of Cardiovasacular Medicine, in a piece that details the negative effects drinking soda can have on consumer's health and ultimately their lifespan.

Read more


Ibuprofen Could Make Heart Failure Worse, American Heart Association Warns

July 11, 2016

Following the recent publication of guildines from the American Heart Association which urge doctors to check all patients' medications to ensure they aren't inadvertently putting their lives at risk, the Daily Mail hightlights the impacts some common medications can have on worsening heart failure. Mariell Jessup, MD, a professor of Cardiovascular Medicine, is quoted.

Read more


At the Surface

July 8, 2016

Researchers Avery Posey, Laura Johnson and Carl June of Medicine are developing an immunotherapy that uses engineered T cells to target a wide range of solid tumors. (Video)

Read more


Immune System Autocorrect Feature Reverses Autoimmune Disease in Mice

July 7, 2016

A Penn team reports in Science on how to adapt a highly successful immune system approach to fight cancer against a debilitating skin disease. Aimee S. Payne, MD, PhD, an associate professor of Dermatology, Michael C. Milone, MD, PhD, an assistant professor of Pathology and Laboratory Medicine, and postdoctoral fellow Christoph T. Ellebrecht, MD, were all mentioned in the article.

Read more


New Therapy Treats Autoimmune Disease Without Harming Normal Immunity

June 30, 3016

A Penn team reports in Science on how to adapt a highly successful immune system approach to fight cancer against a debilitating skin disease. Aimee S. Payne, MD, PhD, the Albert M. Kligman Associate Professor of Dermatology, Michael C. Milone, MD, PhD, an assistant professor of Pathology and Laboratory Medicine, and postdoctoral fellow Christoph T. Ellebrecht, MD, were all mentioned in news stories.

Read more


Double Targeted CAR-T Scores in Preclinical Cancer Study

June 30, 2016

To date, T cells modified to express chimeric antigen receptors (CARs) have been too indiscriminate to use against solid tumors. Better-targeted CAR T cells, however, have been demonstrated in a preclinical study led by Avery Posey, PhD, an instructor in Pathology and Laboratory Medicine, Laura Johnson, PhD, director of the Solid Tumor Immunotherapy Laboratory in the Center for Cellular Immunotherapies, and Carl June, MD, the Richard W. Vague Professor in Immunotherapy and director of the Center for Cellular Immunotherapies.

Read more


Game-changer

June 29, 2016

George Shaw and Hui Li of the Perelman School of Medicine have developed an improved research tool that will give scientists a better way to test possible HIV vaccines.

Read more


A Closer Look at CRISPR

June 24, 2016

Carl June, MD, a professor of Immunotherapy in Pathology and Laboratory Medicine, is quoted in a STAT article that takes a deeper dive into the potential hurdles associated with the gene-editing technique CRISPR, including the commonly raised concern over whether the tool may edit out the wrong DNA.

Read more


CAR-T Optimized to Target Solid Tumors in Animal Models

June 23, 2016

Better-targeted CAR T cells have been demonstrated in a preclinical study led by Avery Posey, PhD, an instructor in Pathology and Laboratory Medicine; Laura Johnson, PhD, director of the Solid Tumor Immunotherapy Laboratory in the Center for Cellular Immunotherapies, and Carl June, MD, the Richard W. Vague Professor in Immunotherapy and director of the Center for Cellular Immunotherapies. The CAR T cells were engineered to aim at a truncated carbohydrate molecule expressed in a variety of cancers.

Read more


Top Honor: George Hajishengallis Receives NIH MERIT Award

June 10, 2016

George Hajishengallis of Dental has been recognized by the National Institutes of Health for “distinctly superior” research and productivity in his work on periodontitis.

Read more


Archived News